Advanced search
Publication Cover
Postgraduate Medicine Volume 123, 2011 - Issue 4
Submit an article Journal homepage
53
Views
8
CrossRef citations to date
0
Altmetric
Clinical Features

Clinical Outcomes during Opioid Titration following Initiation with or Conversion to Remoxy®, an Extended-Release Formulation of Oxycodone

Carl L. Roland King Pharmaceuticals Research and Development, Inc., Cary, NC (acquired by Pfizer Inc in March 2011)Correspondence[email protected]
, PharmD,
Beatrice Setnik King Pharmaceuticals Research and Development, Inc., Cary, NC (acquired by Pfizer Inc in March 2011)
, PhD,
Jody M. Cleveland King Pharmaceuticals Research and Development, Inc., Cary, NC (acquired by Pfizer Inc in March 2011)
, MS &
David A. Brown King Pharmaceuticals Research and Development, Inc., Cary, NC (acquired by Pfizer Inc in March 2011)
, PhD, MPH
Pages 148-159 | Published online: 13 Mar 2015

References

  • . Chou R, Fanciullo GJ, Fine PG,; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
  • . Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010;10(2):85–93
  • . Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage. 2009;38(3):409–417
  • . Miaskowski C, Bair MJ, Chou R,. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed. New York, NY: American Pain Society; 2008
  • . Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag. 2008;4(4):213–250
  • . Zamloot M, Chao W, Kang L, Ross J, Fu R. Remoxy: a novel formulation of extended-release oxycodone developed using the ORADUR technology. J Appl Res. 2010;10(3):88–96
  • . Friedmann N, Klutzartiz V, Webster LR. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag. In press
  • . Friedmann N, Klutzartiz V, Webster LR. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthitis of low back pain. Pain Med. 2011;12(5):755–760
  • . International Conference on Harmonisation. ICH Guidelines; 2011
  • . Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2008;36(2):343–352
  • . Palangio M, Northfelt DW, Portenoy RK,. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23(5):355–368
  • . Katz N, Rauck R, Ahdieh H,. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128
  • . Korff MV, Saunders K, Thomas Ray G,. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–527
  • . OxyContin (oxycodone HCl controlled-release tablets) [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010
  • . Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158
  • . Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–1594
  • . Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35(2):214–228
  • . DURAGESIC® (Fentanyl Transdermal System) [package insert]. Raritan, NJ: PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2009

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.